Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/7/2020 (updated 3/29/2024)
This toolkit contains clinical materials targeting treatment of substance use disorder in the acute care setting.
Posted 9/22/2020 (updated 3/29/2024)
The Learning Collaboratives Town Hall took place on September 15, 2020.
Posted 9/4/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy and Learning Collaborative Orientation Webinar took place on August 25, 2020. Please find the presentation and recording posted here.
Posted 12/3/2019 (updated 3/28/2024)
Billing Behavioral Health Medicaid Services Under Managed Care in New York State.
Posted 5/11/2020 (updated 3/28/2024)
This fact sheet describes changes to Oregon Health Authority (OHA) reimbursement for Medication-Assisted Treatment drugs administered to fee-for-service Oregon Health Plan members, effective January 1, 2019.
Posted 5/11/2020 (updated 3/28/2024)
Medication assisted treatment (MAT) will be offered to patients who have a current diagnosis of opioid use disorder (OUD), moderate to severe, and who meet predetermined criteria.
Posted 12/20/2022 (updated 3/27/2024)
The Centers for Medicare & Medicaid Services (CMS) recently released the Calendar Year (CY) 2023 Physician Fee Schedule. This rule makes policy updates which may increase accessibility of behavioral health services and telehealth services in rural areas. CMS subject matter experts from the Hospital and Ambulatory Policy Group (HAPG) presented on the behavioral health and telehealth updates in the rule during the webinar held on Wednesday, December 14, 2022.
Posted 11/11/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the 2022-2023 RCORP-TA Data Learning Collaborative (LC) for grantees to come together and share knowledge, talk through challenges, and build relationships with one another. This LC will build upon the foundation established in the prior 2022 RCORP-TA Data Learning Collaborative.